Key result
Newer antiplatelet agents including GP IIb/IIIa inhibitors are undergoing evaluation for major cardiovascular disorders.
Population
Patients with major cardiovascular disorders, including unstable angina pectoris, acute myocardial…
Design
Review
Authors
Loading...
Encourages targeted development of GP IIb/IIIa antagonists; leaves open their comparative efficacy and role versus established therapies.
This review highlights the development of newer, more potent antiplatelet agents, specifically targeting the GP IIb/IIIa receptor, for the management of major cardiovascular disorders.
Tm et al. (1997) conducted a review in Cardiovascular disorders. Newer antiplatelet agents (glycoprotein IIb/IIIa receptor antagonists) was evaluated. Newer antiplatelet agents, particularly glycoprotein IIb/IIIa receptor antagonists, are being developed and evaluated for the treatment and prevention of major cardiovascular disorders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: